SWP
ABEO icon

Stratos Wealth Partners’s Abeona Therapeutics ABEO Stock Holding History

Stratos Wealth Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,600
Closed -$13K – 1191
2022
Q1 		$13K Buy
+1,600
New +$11K ﹤0.01% 1259

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Stratos Wealth Partners's ABEO Position: Q2 2022 in Review

Stratos Wealth Partners sold out of Abeona Therapeutics (ABEO) in Q2 2022, closing a stake of 1,600 shares — an estimated $13K sold.

Stratos Wealth Partners first reported a position in ABEO in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 42 funds tracked by Wall St. Rank hold ABEO as of Q2 2022.

  • Stratos Wealth Partners reported no remaining Abeona Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Stratos Wealth Partners sold 1,600 Abeona Therapeutics shares in Q2 2022, an estimated $13K.
  • Stratos Wealth Partners first reported a position in Abeona Therapeutics in Q1 2022 and held it in 1 quarter.
  • Stratos Wealth Partners's Abeona Therapeutics position peaked at $13K in Q1 2022.
  • 42 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2022.

Based on Stratos Wealth Partners's 13F filing for Q2 2022, filed 22 Jul 2022.